BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen N.A., Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders, has successfully completed its reverse merger into Valentis, Inc. on July 13, 2007. As a result, the Company plans to change its name to Urigen Pharmaceuticals, Inc. However, until such event unfolds, the Company will continue to trade on the Bulletin Board under the Valentis Inc. symbol (VLTS).
